Methods of Extracorporeal Immunopharmacotherapy: From General Medical Clinical Practice to Oncologic Practice (Literature Review)
DOI:
https://doi.org/10.61841/abz07d50Keywords:
Malignant Tumors, Plasmapheresis, Cervical Cancer (CC), Extracorporeal Immunopharmacotherapy (EIPhT)Abstract
The review presents the results of the application of extracorporeal immunopharmacotherapy (EIFT) techniques in medical practice for the treatment of infectious and autoimmune diseases, as well as septic complications. EIFT studies as an accompanying therapy in the treatment of malignant tumors are presented. The widespread practical implementation of EIFT is hindered by inadequate clinical testing for various diseases, a small spectrum of studied drugs, and the lack of adequate methods for predicting efficacy. In our own studies on the example of patients with cervical cancer of the II-III stages, it was shown that the immunotherapy regimen is most effective in complex treatment, including intermittent plasmapheresis followed by EIFT, which improves blood counts, increases leuko- and lymphopoiesis, normalizes cellular and humoral immunity, reduces the main clinical manifestations of chemotherapy toxicity, improves indicators of the subjective state of patients and their quality of life, and also allows you to increase indicators of the five-year survival rate.
Downloads
References
[1] Alimkhodzhaeva L.T. Cycloferon and extracorporeal therapy in optimization of neoadjuvant PCT of
locally advanced breast cancer // Medical Journal of Uzbekistan. 2007;1:54-57.
[2] Antoneeva I.I. Immunopathology and immunotherapy of ovarian cancer. Monograph. -Ulyanovsk,
2007; 143 p.
[3] Ausheva T.V. Autohemochemotherapy in combination with extracorporeal magnetic blood processing in
The complex treatment of malignant bone tumors: diss... cand.med. sciences. - Rostov-on-Don, 2005.
[4] Voinov V.A. Tactics of efferent therapy in sepsis // Bulletin of Surgery named after I.I. Grekov. 2013;2:75-
78.
[5] Gushchin N.S., Leskov V.P., Prozorovsky N.S. Experimental substantiation of extracorporeal
immunopharmacotherapy // Actual issues of immunopharmacotherapy. Moscow, 1987. P. 71-82.
[6] Zharinov G.M., Molchanov O.E., Agafonova M.V., Rumyantseva S.Yu. The first experience of the local
Immunotherapy of oncogynecological patients // Cytokines and inflammation. 2002. V.1. –№2. –P.75.
[7] Zinchenko S.V. Immunomodulators in the treatment of cancer patients (literature review) // Volga
Oncology Bulletin. 2014;1:57-64.
[8] Kamyshov S.V., Pulatov D.A., Nishanov D.A., Yuldasheva N.Sh.
[9] The effect of the expression level of tumor markers on the results of treatment of patients with cervical
cancer who received accompanying immunotherapy // Evraz. oncologist. magazine. 2017; 1:68-76.
[10] Kamyshov S.V., Pulatov D.A., Yuldasheva N.Sh. Study of the role of extracorporeal
immunopharmacotherapy in reducing the toxic effects of chemoradiotherapy in patients with cervical
cancer //Evraz. oncologist. magazine. 2015;4. –V,7. –P.28-34.
[11] Kiseleva E.A., Volkova S.D., Chechetkin A.V. The development of methods of gravitational blood surgery
in a specialized medical institution // Herald of the Blood Service of Russia. 2016; 3:10-14.
[12] Clinical use of extracorporeal treatment methods / Ed. N.N. Kalinin. - Moscow: Trekpor Technology,
2006.168 p.
[13] Korotky N.G., Ujuhu V.Yu., Flaks G.A. The first experience of using cytapheresis with extracorporeal therapy with leukinferon in patients with psoriasis // Russian Journal of Skin and Sexually Transmitted Diseases. 1998;3:36-38.
[14] Kostyuchenko A.L. Efferent therapy. - St. Petersburg: Foliant, 2000. –432 p.
[15] Leskov V.P., Gushchin I.S. Extracorporeal immunopharmacotherapy // Pulmonology. 1994;4:10-14.
[16] Mendelenko M.M., Kravchenko I.N., Agadzhanyan K.V., Kravchenko A.I. Obtaining cytokines from blood
leukocytes activated by cycloferon // Ross. Immunologist. Magazine. 2001;6. V.4. –P.377-382.
[17] Nikogosyan S.O., Kuznetsov V.V. Ovarian cancer: diagnostic issues and modern treatment methods //Doctor. 2010;9:2-9.
[18] Popovich A.M. Immunotherapy in oncology. Handbook on immunotherapy for a practitioner. -SPb:
Dialog, 2002, pp. 335-352.
[19] Romanes M.A. Extracorporeal immunopharmacotherapy of psoriasis patients: diss... cand. med. sciences. –
Moscow, 2010.
[20] Snezhko T.A. Extracorporeal immunotherapy in the complex treatment of patients with relapses and
Refractory Hodgkin's lymphoma: diss... cand. med. sciences. Rostov-on-Don—2015.
[21] Sumina D.S. Clinical and immunological efficacy of extracorporeal immunopharmacotherapy in the
Complex treatment of psoriasis: author. dis. Cand. med. -Kursk, 2009.—24 p.
[22] Yudina S.M. Extracorporeal immunopharmacotherapy of patients with sepsis and severe purulent infection
// Bulletin of Intensive Therapy. 1995;2:44-48.
[23] Yarustovsky MB, Abrahamyan MV, Krotenko NP, Komardina EV. Methods of molecular transfusiology in
intensive care of critical conditions // RAMS. 2016;4:13-19.
[24] Bambauer R., Latzo R., Schiel R. Therapeutic plasma exchange and selective plasma separation methods.
Fundamental technologies, pathology, and clinical results. Pabst Science Publishers, Lengerich/Berlin,
2013.—P. 395–402.
[25] Bhardwaj N. Harnessing the immune system to treat cancer // J. Clin. Invest. 2007. –V.117. –P.1130–1136.
[26] DiSaia P.J., Creasman W.T. (eds.). Clinical gynecologic oncology.—7th - Mosby Elsevier, 2007. -- 812
p.
[27] Gattinoni L., Powell D.J., Rosenberg S.A., Restifo N.P. Adoptive immunotherapy for cancer: building on
success // Nat. Rev. Immunol. - 2006. - N6. - P. 383–393.
[28] Gavrusev A., Strotsky A., Malashchitsky D. Extracorporeal magnetic therapy for the treatment of chronic
prostatitis // Eur. Urol. Suppl. 2017. -N16. –V.5. –P.2192.
[29] Panagiotou A., Gaiao S., Cruz D.N. Extracorporeal therapies in sepsis // J. Intensive Care Med. 2013. –N5.
–V.28. –P.281-295.
[30] Rosenberg S., Restifo N., Yang J., Morgan R., Dudley M. Adoptive cell transfer: a clinical path to effective cancer immunotherapy // Nature Reviews Cancer. –2008. –N8. –P.299–308.
[31] Sakuraba A., Naganuma M., Hibi T., Ishii H. Intensive therapy of granulocyte and monocyte absorption apheresis induces rapid remission in patients with ulcerative colitis // Gastroenterology. -2003. -N4. –V.124. -P. 1379.
[32] Yoshioka S., Fujiwara H., Nakayama T.I.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
